Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Everolimus (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Apr 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 10 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 31 Aug 2018 Biomarkers information updated